Kaleido Biosciences (KLDO) Competitors $0.0001 0.00 (0.00%) As of 05/20/2026 03:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock KLDO vs. MVLA, ICCT, ELYS, GROM, and KBNTShould you buy Kaleido Biosciences stock or one of its competitors? MarketBeat compares Kaleido Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kaleido Biosciences include Movella (MVLA), iCoreConnect (ICCT), Elys BMG Group (ELYS), Grom Social Enterprises (GROM), and Kubient (KBNT). These companies are all part of the "computer software" industry. KLDO vs. MVLAKLDO vs. ICCTKLDO vs. ELYSKLDO vs. GROMKLDO vs. KBNTHow does Kaleido Biosciences compare to Movella?Movella (NASDAQ:MVLA) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings. Do institutionals and insiders hold more shares of MVLA or KLDO? 40.9% of Movella shares are held by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are held by institutional investors. 20.0% of Movella shares are held by insiders. Comparatively, 9.0% of Kaleido Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor MVLA or KLDO? In the previous week, Movella's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score. Company Overall Sentiment Movella Neutral Kaleido Biosciences Neutral Which has more risk & volatility, MVLA or KLDO? Movella has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Is MVLA or KLDO more profitable? Company Net Margins Return on Equity Return on Assets MovellaN/A N/A N/A Kaleido Biosciences N/A N/A N/A Which has better earnings and valuation, MVLA or KLDO? Movella has higher earnings, but lower revenue than Kaleido Biosciences. Movella is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMovella-$559K-0.21-$220K-$0.62N/AKaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A SummaryMovella and Kaleido Biosciences tied by winning 4 of the 8 factors compared between the two stocks.How does Kaleido Biosciences compare to iCoreConnect?iCoreConnect (NASDAQ:ICCT) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings. Which has more risk & volatility, ICCT or KLDO? iCoreConnect has a beta of 33.29, indicating that its stock price is 3,229% more volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Which has stronger valuation & earnings, ICCT or KLDO? iCoreConnect has higher revenue and earnings than Kaleido Biosciences. Kaleido Biosciences is trading at a lower price-to-earnings ratio than iCoreConnect, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiCoreConnect$11.05M0.00-$15.55M-$44.40N/AKaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A Does the media refer more to ICCT or KLDO? In the previous week, iCoreConnect's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score. Company Overall Sentiment iCoreConnect Neutral Kaleido Biosciences Neutral Do institutionals & insiders believe in ICCT or KLDO? 13.4% of iCoreConnect shares are held by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are held by institutional investors. 59.4% of iCoreConnect shares are held by company insiders. Comparatively, 9.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ICCT or KLDO more profitable? Kaleido Biosciences has a net margin of 0.00% compared to iCoreConnect's net margin of -263.12%. Kaleido Biosciences' return on equity of 0.00% beat iCoreConnect's return on equity.Company Net Margins Return on Equity Return on Assets iCoreConnect-263.12% -1,451.73% -171.32% Kaleido Biosciences N/A N/A N/A SummaryKaleido Biosciences beats iCoreConnect on 6 of the 11 factors compared between the two stocks.How does Kaleido Biosciences compare to Elys BMG Group?Kaleido Biosciences (NASDAQ:KLDO) and Elys BMG Group (NASDAQ:ELYS) are both small-cap computer software companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Does the media prefer KLDO or ELYS? In the previous week, Elys BMG Group's average media sentiment score of 0.64 beat Kaleido Biosciences' score of 0.00 indicating that Elys BMG Group is being referred to more favorably in the news media. Company Overall Sentiment Kaleido Biosciences Neutral Elys BMG Group Positive Is KLDO or ELYS more profitable? Company Net Margins Return on Equity Return on Assets Kaleido BiosciencesN/A N/A N/A Elys BMG Group N/A N/A N/A Which has preferable valuation & earnings, KLDO or ELYS? Elys BMG Group has higher revenue and earnings than Kaleido Biosciences. Elys BMG Group is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaleido Biosciences$1.10M0.00-$95.48M-$2.24N/AElys BMG Group$43.86M0.00-$18.26M-$0.27N/A Which has more risk & volatility, KLDO or ELYS? Kaleido Biosciences has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Elys BMG Group has a beta of 13.25, meaning that its share price is 1,225% more volatile than the broader market. Do institutionals and insiders believe in KLDO or ELYS? 81.6% of Kaleido Biosciences shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by company insiders. Comparatively, 18.5% of Elys BMG Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryElys BMG Group beats Kaleido Biosciences on 6 of the 9 factors compared between the two stocks.How does Kaleido Biosciences compare to Grom Social Enterprises?Kaleido Biosciences (NASDAQ:KLDO) and Grom Social Enterprises (NASDAQ:GROM) are both small-cap computer software companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Is KLDO or GROM more profitable? Company Net Margins Return on Equity Return on Assets Kaleido BiosciencesN/A N/A N/A Grom Social Enterprises N/A N/A N/A Which has better valuation and earnings, KLDO or GROM? Grom Social Enterprises has higher revenue and earnings than Kaleido Biosciences. Kaleido Biosciences is trading at a lower price-to-earnings ratio than Grom Social Enterprises, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaleido Biosciences$1.10M0.00-$95.48M-$2.24N/AGrom Social Enterprises$3.72M0.00-$12.53M-$11.67N/A Which has more risk and volatility, KLDO or GROM? Kaleido Biosciences has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Grom Social Enterprises has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Does the media refer more to KLDO or GROM? In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled Grom Social Enterprises'average media sentiment score. Company Overall Sentiment Kaleido Biosciences Neutral Grom Social Enterprises Neutral Do insiders & institutionals hold more shares of KLDO or GROM? 81.6% of Kaleido Biosciences shares are held by institutional investors. Comparatively, 15.9% of Grom Social Enterprises shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by insiders. Comparatively, 0.0% of Grom Social Enterprises shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryGrom Social Enterprises beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.How does Kaleido Biosciences compare to Kubient?Kubient (NASDAQ:KBNT) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Is KBNT or KLDO more profitable? Company Net Margins Return on Equity Return on Assets KubientN/A N/A N/A Kaleido Biosciences N/A N/A N/A Which has more volatility and risk, KBNT or KLDO? Kubient has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Do institutionals & insiders hold more shares of KBNT or KLDO? 13.9% of Kubient shares are held by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are held by institutional investors. 22.3% of Kubient shares are held by company insiders. Comparatively, 9.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher earnings & valuation, KBNT or KLDO? Kubient has higher revenue and earnings than Kaleido Biosciences. Kubient is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKubient$1.17M0.00-$13.62M-$0.17N/AKaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A Does the media refer more to KBNT or KLDO? In the previous week, Kubient's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score. Company Overall Sentiment Kubient Neutral Kaleido Biosciences Neutral SummaryKubient beats Kaleido Biosciences on 5 of the 8 factors compared between the two stocks. Get Kaleido Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLDO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLDO vs. The Competition ExportMetricKaleido BiosciencesBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$4K$460.28M$6.30B$12.11BDividend YieldN/A3.87%2.80%5.36%P/E Ratio0.003.8320.8125.31Price / Sales0.007,349.38530.2071.06Price / CashN/A13.1343.1855.00Price / BookN/A82.869.916.94Net Income-$95.48M-$96.07M$3.55B$335.25M7 Day PerformanceN/A-0.33%-0.77%-1.38%1 Month PerformanceN/A-0.30%-1.13%0.09%1 Year PerformanceN/A69.91%33.74%32.51% Kaleido Biosciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLDOKaleido BiosciencesN/A$0.00flatN/A-50.0%$4K$1.10MN/A80MVLAMovellaN/A$0.00flatN/A-45.2%$15K-$559KN/A3ICCTiCoreConnectN/A$0.00flatN/AN/A$5K$11.05MN/A41ELYSElys BMG GroupN/A$0.00flatN/A-75.0%$4K$43.86MN/A90GROMGrom Social EnterprisesN/AN/AN/AN/A$1K$3.72MN/A450 Related Companies and Tools Related Companies Movella Competitors iCoreConnect Competitors Elys BMG Group Competitors Grom Social Enterprises Competitors Kubient Competitors Alfi Competitors AppTech Payments Competitors Arbe Robotics Competitors Arogo Capital Acquisition Competitors Arogo Capital Acquisition Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLDO) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kaleido Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
